Scoring results of docking afatinib, osimertinib, and gefitinib with EGFR kinase domain mutants molecules, respectively
| Drug . | EGFREx19Del . | EGFREx19Del+G724S . | ||
|---|---|---|---|---|
| Goldscore . | ASP . | Goldscore . | ASP . | |
| Osimertinib | 68.66 ± 2.82 | 24.08 ± 4.05 | 66.57 ± 6.10 | 26.20 ± 4.20 |
| Gefitinib | 56.45 ± 7.22 | 32.26 ± 4.98 | 56.23 ± 3.88 | 26.88 ± 1.93 |
| Afatinib | 56.09 ± 11.40 | 20.36 ± 7.60 | 56.02 ± 3.63 | 25.49 ± 3.64 |
| Drug . | EGFREx19Del . | EGFREx19Del+G724S . | ||
|---|---|---|---|---|
| Goldscore . | ASP . | Goldscore . | ASP . | |
| Osimertinib | 68.66 ± 2.82 | 24.08 ± 4.05 | 66.57 ± 6.10 | 26.20 ± 4.20 |
| Gefitinib | 56.45 ± 7.22 | 32.26 ± 4.98 | 56.23 ± 3.88 | 26.88 ± 1.93 |
| Afatinib | 56.09 ± 11.40 | 20.36 ± 7.60 | 56.02 ± 3.63 | 25.49 ± 3.64 |
Abbreviations: ASP, the Astex Statistical Potential; EGFR, epidermal growth factor receptor; Ex19Del, Exon 19 Deletion.
Scoring results of docking afatinib, osimertinib, and gefitinib with EGFR kinase domain mutants molecules, respectively
| Drug . | EGFREx19Del . | EGFREx19Del+G724S . | ||
|---|---|---|---|---|
| Goldscore . | ASP . | Goldscore . | ASP . | |
| Osimertinib | 68.66 ± 2.82 | 24.08 ± 4.05 | 66.57 ± 6.10 | 26.20 ± 4.20 |
| Gefitinib | 56.45 ± 7.22 | 32.26 ± 4.98 | 56.23 ± 3.88 | 26.88 ± 1.93 |
| Afatinib | 56.09 ± 11.40 | 20.36 ± 7.60 | 56.02 ± 3.63 | 25.49 ± 3.64 |
| Drug . | EGFREx19Del . | EGFREx19Del+G724S . | ||
|---|---|---|---|---|
| Goldscore . | ASP . | Goldscore . | ASP . | |
| Osimertinib | 68.66 ± 2.82 | 24.08 ± 4.05 | 66.57 ± 6.10 | 26.20 ± 4.20 |
| Gefitinib | 56.45 ± 7.22 | 32.26 ± 4.98 | 56.23 ± 3.88 | 26.88 ± 1.93 |
| Afatinib | 56.09 ± 11.40 | 20.36 ± 7.60 | 56.02 ± 3.63 | 25.49 ± 3.64 |
Abbreviations: ASP, the Astex Statistical Potential; EGFR, epidermal growth factor receptor; Ex19Del, Exon 19 Deletion.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
